Daily startup and blockchain data-wiki with interviews, Q&A's & discussions about funding rounds & investors.

RaisedToday moderators manually update and approve wiki edits - check back every 1-2h for approved submissions.

Contributed by laura998

Glenn Tillotson

Scientific Advisory Board

Spero Therapeutics Total Funding ($256,400,000)

Wikipedia Link

Trained in medical microbiology and infectious diseases in the UK Glenn Tillotson has almost 30 years pharmaceutical experience in various areas including clinical research, commercialization, medical affairs scientific communications including publication planning ,strategic drug development, life cycle management and global launch programs. Mainly in the field of anti-infectives Dr. Tillotson has been instrumental in the development of ciprofloxacin and moxifloxacin as well as other drugs in the Bayer portfolio for whom he worked for 15 years. In 2003, Glenn worked with Genesoft on the commercialization and launch of gemifloxacin (Factive), leading to the development of Oscient. From late 2003 to early 2006 he focused his efforts on the launch of gemifloxacin into the US clinical practice as well as co-marketing and business development deals globally. In April 2006, Dr Tillotson joined Replidyne Inc. as Executive Director of Scientific Affairs working on faropenem, REP 8839 and REP 3123. In June 2008 Dr. Tillotson became the Head of Medical Affairs at ViroPharma Incorporated where he oversaw educational, publication and other related activities for Vancocin, maribavir and Cinryze. In 2009, Dr. Tillotson was honored by the American College of Chest Physicians with the Alfred Soffer Award for contributions to the College. In February 2011, he joined Optimer Pharmaceuticals as Senior Vice President of Medical Affairs and built a 15 member team to support the launch of fidaxomicin (Dificid). In May 2012, he left Optimer to enable him to concentrate on a variety of projects which encompass drug development planning, publication planning, and new initiatives on C difficile and other unmet clinical needs. He has been a member of the Scientific Steering Committee for the GTCBio Annual Summit on Anti-infective Partnering for the past 6 years. He is a member of the Scientific Steering committee for the 2014 Anaerobe Society meeting in July. He has published over 140 peer-reviewed manuscripts, presented >270 scientific posters and is on several journal Editorial Advisory Boards including the Lancet Infectious Disease and F1000.